<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="120977">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01842971</url>
  </required_header>
  <id_info>
    <org_study_id>PI 2012-843-0028</org_study_id>
    <secondary_id>A41707-36</secondary_id>
    <nct_id>NCT01842971</nct_id>
  </id_info>
  <brief_title>ALPPS (Liver Partition and Portal Vein Ligation) for Two-stage Hepatectomy for Colorectal Liver Metastasis</brief_title>
  <official_title>Associating Liver Partition and Portal Vein Ligation (ALPPS) for Potentially Resectable Liver Metastasis From Colorectal Cancer: Prospective Evaluation of the Early Two-stage Hepatectomy by the Simon's Methods</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <authority>France: Committee for the Protection of Personnes</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is evaluate the feasibility of early two-stage hepatectomy in patients
      with liver metastasis from colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In France, each year around 36,000 new cases of colorectal cancers are registered
      responsible in 16,000 deaths because of liver metastasis.

      In case of bilobar metastasis, classic two-stage hepatectomy with portal embolization could
      be performed.

      An alternative to the classic surgery, early two stage hepatectomy, could be proposed to
      simplify the patient's management and to improve the resectability.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>number of complete surgical procedure</measure>
    <time_frame>postoperative week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>the number of complete surgical procedure is defined as the number of patients in whom the two stage hepatectomy is complete.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall mortality</measure>
    <time_frame>one year after the two stage hepatectomy</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>the overall mortality is defined as the number of patients who are dead at one year after the surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patient with hepatocellular insufficiency</measure>
    <time_frame>postoperative day 30</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>the hepatocellular insufficiency is defined by a prothrombin rate below 50%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall morbidity</measure>
    <time_frame>postoperative day 30</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>the overall morbidity is classified according to the Dindo Clavien classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>preoperative liver volumetry</measure>
    <time_frame>one week prior to the surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>the remnant liver volume is evaluated with the Myrian Software and calculated by the radiologist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>the day before the first stage surgery and the day before the second stage surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>the quality of life is evaluated thanks to the EORTC QLQ C30 LMC 21 form the day before the first stage surgery and the day before the second stage surgery.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>two stage hepatectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the two stage hepatectomy is defined as a two step procedure: first step: hepatotomy with ligature of the right branch of the portal vein second step (one week after the first step): right hepatectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>two stage hepatectomy</intervention_name>
    <arm_group_label>two stage hepatectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  potentially resectable liver metastasis from colorectal cancer

          -  portal embolisation required

          -  older than 18 years old

        Exclusion Criteria:

          -  synchronous surgery on the colon or the rectum

          -  extra hepatic metastasis

          -  history of hepatectomy

          -  pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jean marc regimbeau, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Amiens University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>jean marc regimbeau, MD, PhD</last_name>
    <phone>+33322668300</phone>
    <email>regimbeau.jean-marc@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Amiens University Hospital</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jean marc regimbeau, MD, PhD</last_name>
      <phone>+33 3 22 66 83 00</phone>
      <email>regimbeau.jean-marc@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>jean marc regimbeau, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 26, 2013</lastchanged_date>
  <firstreceived_date>April 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>two stage hepatectomy</keyword>
  <keyword>liver metastasis</keyword>
  <keyword>colorectal cancer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
